Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer

Cancer Letters

Volumn 321, Issue 2, 2012, Pages 101-109

  Reckamp, Karen L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Non small cell lung cancer; Second line therapy; Tyrosine kinase inhibitor; Vascular disrupting agent

Indexed keywords

AFLIBERCEPT; ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; AV 0005; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; IXABEPILONE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PLINABULIN; POTASSIUM; RAMUCIRUMAB; SORAFENIB; SUNITINIB; THYROTROPIN; UNCLASSIFIED DRUG; VADIMEZAN; VANDETANIB; ZAL TRAP;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APPLICATION SITE PAIN; ARTERIAL THROMBOEMBOLISM; BLEEDING; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONSTIPATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART ARREST; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PNEUMONIA; PNEUMOTHORAX; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; SHORT SURVEY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VASCULARIZATION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84860918028     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.041     Document Type: Review

References (70)

1. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology™. Non-Small Cell Lung Cancer. V.2.2012. <> (accessed 28.11.11). http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
2. American Cancer Society Cancer Facts & Figures, 2011 2011, American Cancer Society, Atlanta, GA.
3. World Health Organization, Fact Sheet No. 310: The Top Ten Causes of Death. November 2008. <> (accessed 8.10.09). http://www.who.int/mediacentre/factsheets/fs310_2008.pdf.
4. Jiang Y., Owonikoko T.K., Ramalingam S.S., Khuri F.R., Belani C.P. What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. Ther. Adv. Med. Oncol. 2010, 2:229-235.
5. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., Johnson D.H., Laskin J.L., Masters G., Milton D., Nordquist L., Pfister D.G., Piantadosi S., Schiller J.H., Smith R., Smith T.J., Strawn J.R., Trent D., Giaccone G. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:6251-6266.
6. Socinski M.A., Baggstrom M.Q., Hensing T.A. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin. Adv. Hematol. Oncol. 2003, 1:33-38.
7. Tassinari D., Scarpi E., Sartori S., Tamburini E., Santelmo C., Tombesi P., Lazzari-Agli L. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 2009, 135:1596-1609.
8. Di Maio M., Chiodini P., Georgoulias V., Hatzidaki D., Takeda K., Wachters F.M., Gebbia V., Smit E.F., Morabito A., Gallo C., Perrone F., Gridelli C. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:1836-1843.
9. Maione P., Rossi A., Bareschino M.A., Sacco P.C., Schettino C., Falanga M., Barbato V., Ambrosio R., Gridelli C. Factors driving the choice of the best second-line treatment of advanced NSCLC. Rev. Recent Clin. Trials 2011, 6:44-51.
10. Noble J., Ellis P.M., Mackay J.A., Evans W.K. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J. Thorac. Oncol. 2006, 1:1042-1058.
11. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., de Marinis F., von Pawel J., Gatzemeier U., Tsao T.C., Pless M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar, Manegold C., Paul S., Paoletti P., Einhorn L., Bunn P.A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004, 22:1589-1597.
12. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353:123-132.
13. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
14. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
15. Folkman J., Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987, 329:671-672.
16. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
17. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev. 2004, 15:229-235.
18. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:159-178.
19. Kano M.R., Morishita Y., Iwata C., Iwasaka S., Watabe T., Ouchi Y., Miyazono K., Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J. Cell Sci. 2005, 118:3759-3768.
20. Nissen L.J., Cao R., Hedlund E.M., Wang Z., Zhao X., Wetterskog D., Funa K., Brakenhielm E., Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007, 117:2766-2777.
21. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
22. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
23. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004, 18:338-340.
24. Gridelli C., Rossi A., Maione P., Rossi E., Castaldo V., Sacco P.C., Colantuoni G. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009, 14:612-620.
25. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J., Archer V., Moore N., Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 2009, 27:1227-1234.
26. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., Leighl N., Mezger J., Archer V., Moore N., Manegold C. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 2010, 21:1804-1809.
27. Herbst R.S., O'Neill V.J., Fehrenbacher L., Belani C.P., Bonomi P.D., Hart L., Melnyk O., Ramies D., Lin M., Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J. Clin. Oncol. 2007, 25:4743-4750.
28. Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., Ziegler K.L., Stella P.J., Rowland K.M., Schild S.E., Zinner R.G. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J. Clin. Oncol. 2010, 28:614-619.
29. Herbst R.S., Ansari R., Bustin F., Flynn P., Hart L., Otterson G.A., Vlahovic G., Soh C.H., O'Connor P., Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
30. Socinski M.A., Langer C.J., Huang J.E., Kolb M.M., Compton P., Wang L., Akerley W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 2009, 27:5255-5261.
31. Gubens M., Akerley W., Lynch T., Langer C.J., Socinski M.A., Colevas A.D., Clement-Duchene C., Wakelee H. A pooled analysis of advanced nonsquamous NSCLC patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J. Thorac. Oncol. 2011, 6. Abstract P3.093.
32. Lockhart A.C., Rothenberg M.L., Dupont J., Cooper W., Chevalier P., Sternas L., Buzenet G., Koehler E., Sosman J.A., Schwartz L.H., Gultekin D.H., Koutcher J.A., Donnelly E.F., Andal R., Dancy I., Spriggs D.R., Tew W.P. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28:207-214.
33. S. Novello, R. Ramlau, V.A. Gorbunova, T.E. Ciuleanu, M. Ozguroglu, T. Goksel, C. Baldotto, J. Bennouna, F.A. Shepherd, G. Scagliotti, Aflibercept in Combination with Docetaxel for Second-line treatment of Locally Advanced or Metastatic Non-small-cell Lung Cancer (NSCLC): Final Results of a Multinational Placebo-controlled Phase III Trial (EFC10261-VITAL). Abstract Associated with Oral Presentation at: the 14th Biennial World Conference on Lung Cancer; July 3-7, 2011; Amsterdam, Netherlands 2011), Abstract O43.06.
34. Leighl N.B., Raez L.E., Besse B., Rosen P.J., Barlesi F., Massarelli E., Gabrail N., Hart L.L., Albain K.S., Berkowitz L., Melnyk O., Shepherd F.A., Sternas L., Ackerman J., Shun Z., Miller V.A., Herbst R.S. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J. Thorac. Oncol. 2010, 5:1054-1059.
35. Spratlin J.L., Cohen R.B., Eadens M., Gore L., Camidge D.R., Diab S., Leong S., O'Bryant C., Chow L.Q., Serkova N.J., Meropol N.J., Lewis N.L., Chiorean E.G., Fox F., Youssoufian H., Rowinsky E.K., Eckhardt S.G. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010, 28:780-787.
36. Camidge D.R., Ballas M.S., Dubey S., Haigentz M., Rosen P.J., Spicer J.F., West H.J., Shah G.D., Youssoufian H., Mita A.C. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2010, 28. Abstract 7588.
37. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., Boffey S.J., Valentine P.J., Curwen J.O., Musgrove H.L., Graham G.A., Hughes G.D., Thomas A.P., Stokes E.S., Curry B., Richmond G.H., Wadsworth P.F., Bigley A.L., Hennequin L.F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62:4645-4655.
38. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., Ryan A.J., Fontanini G., Fusco A., Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62:7284-7290.
39. Herbst R.S., Sun Y., Eberhardt W.E., Germonpre P., Saijo N., Zhou C., Wang J., Li L., Kabbinavar F., Ichinose Y., Qin S., Zhang L., Biesma B., Heymach J.V., Langmuir P., Kennedy S.J., Tada H., Johnson B.E. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010, 11:619-626.
40. Natale R.B., Thongprasert S., Greco F.A., Thomas M., Tsai C.M., Sunpaweravong P., Ferry D., Mulatero C., Whorf R., Thompson J., Barlesi F., Langmuir P., Gogov S., Rowbottom J.A., Goss G.D. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:1059-1066.
41. De Boer R.H., Arrieta O., Yang C.H., Gottfried M., Chan V., Raats J., de Marinis F., Abratt R.P., Wolf J., Blackhall F.H., Langmuir P., Milenkova T., Read J., Vansteenkiste J.F. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 2011, 29:1067-1074.
42. Lee J., Hirsh V., Park K., Qin S., Blajman C.R., Perng R., Emerson L., Langmuir P.B., Manegold C. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). J. Clin. Oncol. 2010, 28. Abstract 7525.
43. Commander H., Whiteside G., Perry C. Vandetanib: first global approval. Drugs 2011, 71:1355-1365.
44. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
45. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., brao Miziara J.E., Balint B., de Marinis F., Keller A., Aren O., Csollak M., Albert I., Barrios C.H., Grossi F., Krzakowski M., Cupit L., Cihon F., DiMatteo S., Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1835-1842.
46. Gatzemeier U., Eisen T., Santoro A., Paz-Ares L., Bennouna J., Liao M., Strauss U.P., Montegriffo E., Ong T.J., Biesma B. Sorafenib (S)+gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Ann. Oncol. 2010, 21:viii7.
47. Molina J.R., Dy G.K., Foster N.R., Allen Ziegler K.L., Adjei A., Rowland K.M., Aubry M., Flynn P.J., Mandrekar S.J., Schild S.E., Adjei A.A. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J. Clin. Oncol. 2011, 29. Abstract 7513.
48. Blumenschein G.R., Gatzemeier U., Fossella F., Stewart D.J., Cupit L., Cihon F., O'Leary J., Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27:4274-4280.
49. Schiller J.H., Lee J.W., Hanna N.H., Traynor A.M., Carbone D.P. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J. Clin. Oncol. 2008, 26. Abstract 8014.
50. Socinski M.A., Scappaticci F.A., Samant M., Kolb M.M., Kozloff M.F. Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel/carboplatin in non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:354-360.
51. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., Govindan R., Atkins J.N., Gillenwater H.H., Pallares C., Tye L., Selaru P., Chao R.C., Scagliotti G.V. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:650-656.
52. Novello S., Scagliotti G.V., Rosell R., Socinski M.A., Brahmer J., Atkins J., Pallares C., Burgess R., Tye L., Selaru P., Wang E., Chao R., Govindan R. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br. J. Cancer 2009, 101:1543-1548.
53. Scagliotti G.V., Krzakowski M., Szczesna A., Strausz J., Makhson A., Reck M., Tye L., Selaru P., Chao R.C., Govindan R. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study. Ann. Oncol. 2010, 21:viii3. Abstract LBA6.
54. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A., Rettig W.J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68:4774-4782.
55. Roth G.J., Heckel A., Colbatzky F., Handschuh S., Kley J., Lehmann-Lintz T., Lotz R., Tontsch-Grunt U., Walter R., Hilberg F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 2009, 52:4466-4480.
56. Reck M., Kaiser R., Eschbach C., Stefanic M., Love J., Gatzemeier U., Stopfer P., von Pawel J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann. Oncol. 2011, 22:1374-1381.
57. Nikolinakos P., Heymach J.V. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol. 2008, 3:S131-S134.
58. Goss G.D., Arnold A., Shepherd F.A., Dediu M., Ciuleanu T.E., Fenton D., Zukin M., Walde D., Laberge F., Vincent M.D., Ellis P.M., Laurie S.A., Ding K., Frymire E., Gauthier I., Leighl N.B., Ho C., Noble J., Lee C.W., Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J. Clin. Oncol. 2010, 28:49-55.
59. NCIC Clinical Trials Group - Site Committee Open/Closed/Planned/On Hold/Withdrawn Studies. Accrual as of: 2011 November 17. <> (accessed 18.11.11). http://www.ctg.queensu.ca/public/Clinical_Trials/ph3_trial_accrual_closed.htm.
60. S. Gadgeel, J. Ruckdeschel, A. Wozniak, D. Hackstock, W. Chen, C. Galasso, A. Burger, P. LoRusso, P. Ivy, M.J. Edelman, Cediranib, A VEGF Receptor 1, 2, and 3 Inhibitor, and Pemetrexed in Patients (pts) with Recurrent Non-small Cell Lung Cancer (NSCLC). Abstract Associated with Oral Presentation at: the 14th Biennial World Conference on Lung Cancer; July 3-7, 2011; Amsterdam, Netherlands 2011), Abstract MO09.04.
61. Kumar R., Knick V.B., Rudolph S.K., Johnson J.H., Crosby R.M., Crouthamel M.C., Hopper T.M., Miller C.G., Harrington L.E., Onori J.A., Mullin R.J., Gilmer T.M., Truesdale A.T., Epperly A.H., Boloor A., Stafford J.A., Luttrell D.K., Cheung M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 2007, 6:2012-2021.
62. Podar K., Tonon G., Sattler M., Tai Y.T., Legouill S., Yasui H., Ishitsuka K., Kumar S., Kumar R., Pandite L.N., Hideshima T., Chauhan D., Anderson K.C. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl. Acad. Sci. USA 2006, 103:19478-19483.
63. Altorki N., Lane M.E., Bauer T., Lee P.C., Guarino M.J., Pass H., Felip E., Peylan-Ramu N., Gurpide A., Grannis F.W., Mitchell J.D., Tachdjian S., Swann R.S., Huff A., Roychowdhury D.F., Reeves A., Ottesen L.H., Yankelevitz D.F. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:3131-3137.
64. Antisoma plc, ATTRACT-1 Phase III Trial of ASA404 Halted Following Interim Analysis, Press Release, March 29, 2010. <> (accessed 27.07.10). http://www.antisoma.com/asm/media/press/pr2010/2010-03-29/.
65. Antisoma plc, Antisoma Announces Outcome of ASA404 ATTRACT-2 Trial, Press Release, November 11, 2010. <> (accessed 24.11.10). http://www.antisoma.com/asm/media/press/pr2010/2010-11-11/.
66. Lara P.N., Douillard J.Y., Nakagawa K., von P.J., McKeage M.J., Albert I., Losonczy G., Reck M., Heo D.S., Fan X., Fandi A., Scagliotti G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:2965-2971.
67. Rudin C.M., Mauer A., Smakal M., Juergens R., Spelda S., Wertheim M., Coates A., McKeegan E., Ansell P., Zhou X., Qian J., Pradhan R., Dowell B., Krivoshik A., Gordon G. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:1075-1082.
68. Nicholson B., Lloyd G.K., Miller B.R., Palladino M.A., Kiso Y., Hayashi Y., Neuteboom S.T. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006, 17:25-31.
69. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., McDonald D.M. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006, 116:2610-2621.
70. Nguewa P.A., Calvo A., Pullamsetti S.S., Banat G.A., Grimminger F., Savai R. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. Expert Opin. Invest. Drugs 2011, 20:61-74.